14 results on '"DasGupta Bhaskar"'
Search Results
2. Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis.
- Author
-
Ponte, Cristina, Serafim, Ana Sofia, Monti, Sara, Fernandes, Elisabete, Lee, Ellen, Singh, Surjeet, Piper, Jennifer, Hutchings, Andrew, McNally, Eugene, Diamantopoulos, Andreas P, Dasgupta, Bhaskar, Schmidt, Wolfgang A, and Luqmani, Raashid Ahmed
- Subjects
THERAPEUTIC use of glucocorticoids ,ANALYSIS of variance ,STATISTICAL correlation ,GIANT cell arteritis ,PATIENT aftercare ,INTERMITTENT claudication ,JAW diseases ,VISION disorders ,SYMPTOMS ,TREATMENT effectiveness ,CROSS-sectional method ,AXILLARY artery ,DESCRIPTIVE statistics ,TEMPORAL arteries ,EVALUATION - Abstract
Objectives To compare the ultrasound characteristics with clinical features, final diagnosis and outcome; and to evaluate the halo size following glucocorticoid treatment in patients with newly diagnosed GCA. Methods Patients with suspected GCA, recruited from an international cohort, had an ultrasound of temporal (TA) and axillary (AX) arteries performed within 7 days of commencing glucocorticoids. We compared differences in clinical features at disease presentation, after 2 weeks and after 6 months, according to the presence or absence of halo sign. We undertook a cross-sectional analysis of the differences in halo thickness using Pearson's correlation coefficient (r) and Analysis of Variance (ANOVA). Results A total of 345 patients with 6 months follow-up data were included; 226 (65.5%) had a diagnosis of GCA. Jaw claudication and visual symptoms were more frequent in patients with halo sign (P =0.018 and P =0.003, respectively). Physical examination abnormalities were significantly associated with the presence of ipsilateral halo (P <0.05). Stenosis or occlusion on ultrasound failed to contribute to the diagnosis of GCA. During 7 days of glucocorticoid treatment, there was a consistent reduction in halo size in the TA (maximum halo size per patient: r =−0.30, P =0.001; and all halos r =−0.23, P <0.001), but not in the AX (P >0.05). However, the presence of halo at baseline failed to predict future ischaemic events occurring during follow-up. Conclusion In newly diagnosed GCA, TA halo is associated with the presence of ischaemic features and its size decreases following glucocorticoid treatment, supporting its early use as a marker of disease activity, in addition to its diagnostic role. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. The impact of disease extent and severity detected by quantitative ultrasound analysis in the diagnosis and outcome of giant cell arteritis.
- Author
-
Monti, Sara, Ponte, Cristina, Pereira, Claudio, Manzoni, Federica, Klersy, Catherine, Rumi, Federica, Carrara, Greta, Hutchings, Andrew, Schmidt, Wolfgang A, Dasgupta, Bhaskar, Caporali, Roberto, Montecucco, Carlomaurizio, and Luqmani, Raashid
- Subjects
BIOMARKERS ,BIOPSY ,CONFIDENCE intervals ,GIANT cell arteritis ,HEADACHE ,INFLAMMATION ,ISCHEMIA ,MATHEMATICAL models ,PROBABILITY theory ,RISK assessment ,THEORY ,QUANTITATIVE research ,COLOR Doppler ultrasonography ,TREATMENT effectiveness ,SEVERITY of illness index ,AXILLARY artery ,DESCRIPTIVE statistics ,TEMPORAL arteries - Abstract
Objectives To develop a quantitative score based on colour duplex sonography (CDS) to predict the diagnosis and outcome of GCA. Methods We selected patients with positive CDS and confirmed diagnosis of GCA recruited into the TA Biopsy (TAB) vs Ultrasound in Diagnosis of GCA (TABUL) study and in a validation, independent cohort. We fitted four CDS models including combinations of the following: number and distribution of halos at the TA branches, average and maximum intima–media thickness of TA and axillary arteries. We fitted four clinical/laboratory models. The combined CDS and clinical models were used to develop a score to predict risk of positive TAB and clinical outcome at 6 months. Results We included 135 GCA patients from TABUL (female: 68%, age 73 (8) years) and 72 patients from the independent cohort (female: 46%, age 75 (7) years). The best-fitting CDS model for TAB used maximum intima–media thickness size and bilaterality of TA and axillary arteries' halos. The best-fitting clinical model included raised inflammatory markers, PMR, headache and ischaemic symptoms. By combining CDS and clinical models we derived a score to compute the probability of a positive TAB. Model discrimination was fair (area under the receiver operating characteristic curve 0.77, 95% CI: 0.68, 0.84). No significant association was found for prediction of clinical outcome at 6 months. Conclusion A quantitative analysis of CDS and clinical characteristics is useful to identify patients with a positive biopsy, supporting the use of CDS as a surrogate tool to replace TAB. No predictive role was found for worse prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease.
- Author
-
Dejaco, Christian, Duftner, Christina, Buttgereit, Frank, Matteson, Eric L., and Dasgupta, Bhaskar
- Subjects
GIANT cell arteritis diagnosis ,IMMUNOSUPPRESSIVE agents ,BIOTHERAPY ,DIAGNOSTIC imaging ,GIANT cell arteritis ,POLYMYALGIA rheumatica ,VASCULITIS ,PHENOTYPES ,DISEASE management ,COMORBIDITY ,DISEASE prevalence ,SYMPTOMS ,DIAGNOSIS - Abstract
GCA and PMR are conditions of older persons that frequently overlap. The traditional concept of GCA has focused on cranial symptoms such as headache and visual disturbance, but extra-cranial manifestations such as constitutional symptoms, polymyalgia and limb claudication have also long been recognized. These symptoms may coincide with cranial GCA, occur as an independent clinical subset [large-vessel (LV) GCA] or overlap with PMR. Imaging studies have demonstrated that up to one-third of patients with PMR have subclinical LV inflammation at disease outset. The implication of this finding for PMR management is unclear. Pathophysiological studies have emphasized the pivotal role of dendritic cells (DCs) and T cells in the pathogenesis of GCA, and the activation of certain pattern recognition receptors on DCs may determine the clinical subset of GCA. In patients with only PMR clinically, it is conceivable that transmural arterial inflammation has either not yet started or is prevented by unexplored regulatory pathways. This concept is supported by vasculitis of peri-adventitial small-vessels and activated DCs in the adventitia of temporal arteries, in the absence of media-infiltrating T cells. This review examines the clinical and pathophysiological spectrum of GCA and its subsets with PMR, the role of newer imaging techniques for GCA diagnosis and the management of these diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
5. Giant cell arteritis: new concepts, treatments and the unmet need that remains.
- Author
-
Coath, Fiona, Gillbert, Kate, Griffiths, Bridget, Hall, Frances, Kay, Lesley, Lanyon, Peter, Luqmani, Raashid, Mackie, Sarah L, Mason, Justin C, Mills, John, Mollan, Susan, Morgan, Ann W, Mukhtyar, Chetan, Quick, Vanessa, Watts, Richard, and Dasgupta, Bhaskar
- Subjects
THERAPEUTIC use of glucocorticoids ,GIANT cell arteritis diagnosis ,TOCILIZUMAB ,BIOPSY ,BLOOD vessels ,COMPUTED tomography ,DEOXY sugars ,DIAGNOSIS ,GIANT cell arteritis ,GLUCOCORTICOIDS ,INTERLEUKINS ,MAGNETIC resonance imaging ,MEDICAL needs assessment ,MEDICAL errors ,RADIOPHARMACEUTICALS ,SERIAL publications ,ULTRASONIC imaging ,DISEASE management ,DISEASE relapse ,TERMINATION of treatment ,TREATMENT effectiveness ,DISEASE remission ,SEVERITY of illness index ,PREDNISOLONE ,CHEMICAL inhibitors ,THERAPEUTICS - Abstract
The article discusses updates on giant cell arteritis (GCA) treatment and management. Topics explored include the approval of tocilizumab (TCZ) by the British National Institute for Health and Care Excellence (NICE) and National Health Service (NHS) England for treating patients with GCA, the clinical guidelines for GCA diagnosis, and the challenges associated with disease activity assessment during therapeutic administration of TCZ.
- Published
- 2019
- Full Text
- View/download PDF
6. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.
- Author
-
Buttgereit, Frank, Dejaco, Christian, Matteson, Eric L., and Dasgupta, Bhaskar
- Subjects
POLYMYALGIA rheumatica ,GIANT cell arteritis ,INFLAMMATION ,INFLAMMATION treatment ,ARTERITIS ,GIANT cell arteritis diagnosis ,CLINICAL trials ,DIAGNOSTIC imaging ,DRUG administration ,GLUCOCORTICOIDS ,META-analysis ,METHOTREXATE ,MONOCLONAL antibodies ,PREDNISONE ,SYSTEMATIC reviews ,DISEASE complications ,DIAGNOSIS ,THERAPEUTICS - Abstract
Importance: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are related inflammatory disorders occurring in persons aged 50 years and older. Diagnostic and therapeutic approaches are heterogeneous in clinical practice.Objective: To summarize current evidence regarding optimal methods for diagnosing and treating PMR and GCA.Evidence Review: MEDLINE, EMBASE, and Cochrane databases were searched from their inception dates to March 30, 2016. Screening by 2 authors resulted in 6626 abstracts, of which 50 articles met the inclusion criteria. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool or American College of Cardiology Foundation/American Heart Association methodology.Findings: Twenty randomized clinical trials for therapy (n = 1016 participants) and 30 imaging studies for diagnosis and/or assessing response to therapy (n = 2080 participants) were included. The diagnosis of PMR is based on clinical features such as new-onset bilateral shoulder pain, including subdeltoid bursitis, muscle or joint stiffness, and functional impairment. Headache and visual disturbances including loss of vision are characteristic of GCA. Constitutional symptoms and elevated inflammatory markers (>90%) are common in both diseases. Ultrasound imaging enables detection of bilateral subdeltoid bursitis in 69% of PMR patients. In GCA, temporal artery biopsy remains the standard for definitive diagnosis. Ultrasound and magnetic resonance imaging (MRI) of large vessels revealing inflammation-induced wall thickening support the diagnosis of GCA (specificity 78%-100% for ultrasound and 73%-97% for MRI). Glucocorticoids remain the primary treatment, but the optimal initial dose and tapering treatment regimens are unknown. According to consensus-based recommendations, initial therapy for PMR is prednisone, 12.5 to 25 mg/day or equivalent, and 40 to 60 mg/day for GCA, followed by individualized tapering regimens in both diseases. Adjunctive methotrexate may reduce cumulative glucocorticoid dosage by 20% to 44% and relapses by 36% to 54% in both PMR and GCA. Use of tocilizumab as additional treatment with prednisone showed a 2- to 4-fold increase in remission rates of GCA in a randomized clinical trial (N = 30).Conclusions and Relevance: Diagnosis of PMR/GCA is made by clinical features and elevated inflammatory markers. In PMR, ultrasound imaging may improve diagnostic accuracy. In GCA, temporal artery biopsy may not be required in patients with typical disease features accompanied by characteristic ultrasound or MRI findings. Consensus-based recommendations suggest glucocorticoids as the most effective therapy for PMR/GCA. Methotrexate may be added to glucocorticoids in patients at risk for relapse and in those with glucocorticoid-related adverse effects or need for prolonged glucocorticoid therapy. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
7. Giant cell arteritis: a review.
- Author
-
Patil, Pravin, Karia, Niral, Jain, Shaifali, and Dasgupta, Bhaskar
- Subjects
GIANT cell arteritis ,VASCULITIS ,CAUCASIAN race ,EYE diseases ,DIAGNOSIS ,MEDICAL imaging systems - Abstract
Giant cell arteritis is the most common vasculitis in Caucasians. Acute visual loss in one or both eyes is by far the most feared and irreversible complication of giant cell arteritis. This article reviews recent guidelines on early recognition of systemic, cranial, and ophthalmic manifestations, and current management and diagnostic strategies and advances in imaging. We share our experience of the fast track pathway and imaging in associated disorders, such as large-vessel vasculitis. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
8. 2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative.
- Author
-
Dasgupta, Bhaskar, Cimmino, Marco A., Kremers, Hilal Maradit, Schmidt, Wolfgang A., Schirmer, Michael, Salvarani, Carlo, Bachta, Artur, Dejaco, Christian, Duftner, Christina, Jensen, Hanne Slott, Duhaut, Pierre, Poór, Gyula, Kaposi, Novák Pál, Mandl, Peter, Balint, Peter V., Schmidt, Zsuzsa, Iagnocco, Annamaria, Nannini, Carlotta, Cantini, Fabrizio, and Macchioni, Pierluigi
- Subjects
- *
ADRENOCORTICAL hormones , *HORMONE therapy , *AGE distribution , *ALGORITHMS , *BLOOD testing , *CLASSIFICATION , *CONFIDENCE intervals , *DIAGNOSIS , *EPIDEMIOLOGY , *LONGITUDINAL method , *MEDICAL cooperation , *MULTIVARIATE analysis , *POLYMYALGIA rheumatica , *RESEARCH , *RESEARCH funding , *ULTRASONIC imaging , *LOGISTIC regression analysis , *DATA analysis , *VISUAL analog scale , *DESCRIPTIVE statistics , *STANDARDS , *SYMPTOMS - Abstract
The objective of this study was to develop European League Against Rheumatism/American College of Rheumatology classification criteria for polymyalgia rheumatica (PMR). Candidate criteria were evaluated in a 6-month prospective cohort study of 125 patients with new-onset PMR and 169 non-PMR comparison subjects with conditions mimicking PMR. A scoring algorithm was developed based on morning stiffness >45 minutes (2 points), hip pain/limited range of motion (1 point), absence of rheumatoid factor and/or anti-citrullinated protein antibody (2 points), and absence of peripheral joint pain (1 point). A score ≥4 had 68% sensitivity and 78% specificity for discriminating all comparison subjects from PMR. The specificity was higher (88%) for discriminating shoulder conditions from PMR and lower (65%) for discriminating RA from PMR. Adding ultrasound, a score ≥5 had increased sensitivity to 66% and specificity to 81%. According to these provisional classification criteria, patients ≥50 years old presenting with bilateral shoulder pain, not better explained by an alternative pathology, can be classified as having PMR in the presence of morning stiffness >45 minutes, elevated C-reactive protein and/or erythrocyte sedimentation rate, and new hip pain. These criteria are not meant for diagnostic purposes. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
9. Concise guidance: diagnosis and management of giant cell arteritis.
- Author
-
Dasgupta, Bhaskar
- Subjects
- *
GIANT cell arteritis , *POLYMYALGIA rheumatica , *STEROID drugs , *MEDICAL emergencies , *MEDICAL societies , *GUIDELINES , *VISION disorders , *THERAPEUTICS , *PREVENTION - Abstract
Giant cell arteritis (GCA) or temporal arteritis (TA) with polymyalgia rheumatica (PMR) is among the most common reasons for long-term steroid prescription. GCA is a critically ischaemic disease, the most common form of vasculitis and should be treated as a medical emergency. Visual loss occurs in up to a fifth of patients, which may be preventable by prompt recognition and treatment. The British Society for Rheumatology (BSR) and the British Health Professionals in Rheumatology (BHPR) have recently published guidelines on the management of PMR. The purpose of this concise guidance is to draw attention to the full guidelines to encourage the prompt diagnosis and urgent management of GCA, with emphasis on the prevention of visual loss. They provide a framework for disease assessment, immediate treatment and referral to specialist care for management and monitoring of disease activity, complications and relapse. [ABSTRACT FROM AUTHOR]
- Published
- 2010
10. Concise guidance: diagnosis and management of polymyalgia rheumatica.
- Author
-
Dasgupta, Bhaskar
- Subjects
- *
POLYMYALGIA rheumatica , *STEROID drugs , *RHEUMATOLOGY , *MEDICAL practice , *RHEUMATOLOGISTS - Abstract
Polymyalgia rheumatica (PMR) is among the most common reasons for long-term steroid prescription with great heterogeneity in presentation, response to steroids and disease course. The British Society for Rheumatology and the British Health Professionals in Rheumatology have recently published guidelines on management of PMR. The purpose of this concise guidance is to draw attention to the full guidelines and provide a safe and specific diagnostic process with advice on management and monitoring -- specifically targeted at general practitioners, general physicians and rheumatologists. [ABSTRACT FROM AUTHOR]
- Published
- 2010
11. BSR and BHPR guidelines for the management of polymyalgia rheumatica.
- Author
-
Dasgupta, Bhaskar, Borg, Frances A., Hassan, Nada, Barraclough, Kevin, Bourke, Brian, Fulcher, Joan, Hollywood, Jane, Hutchings, Andrew, Kyle, Valerie, Nott, Jennifer, Power, Michael, and Samanta, Ash
- Subjects
- *
RHEUMATOLOGY , *POLYMYALGIA rheumatica , *MEDICAL needs assessment , *MYALGIA , *CHRONIC pain , *GUIDELINES , *THERAPEUTICS , *SOCIETIES - Abstract
The article focuses on the guidelines of British Society for Rheumatology (BSR) and British Health Professional in Rheumatology (BHPR) for managing polymyalgia rheumatic (PMR). It says that the guidelines is aiming for a safe and specific diagnostic process for PMR with the use of continued assessment. Moreover, the conditions which decreases the probability of PMR including inflammatory rheumatic diseases, drug-induced myalgia, and chronic pain syndromes are also presented.
- Published
- 2010
- Full Text
- View/download PDF
12. 2015 EULARACR recommendations for polymyalgia rheumatica: the message and next steps.
- Author
-
Steel, Lauren, Bukhari, Marwan, and Dasgupta, Bhaskar
- Subjects
MEDICAL needs assessment ,POLYMYALGIA rheumatica ,MEDICAL protocols ,QUALITY of life ,INDIVIDUALIZED medicine ,PREVENTION ,DIAGNOSIS - Abstract
The authors discuss the 2015 EULAR-ACR collaborative recommendations for the management of polymyalgia rheumatica (PMR) which allow for optimal treatment of PMR to be achieved with a balance between efficacy and minimal undesirable effects of glucocorticoid (GC) therapy. They point out that the treatment of PMR should be based on a shared decision-making between patient and treating physician and cite the need to educate patients with PMR as informed partners in their long-term therapy.
- Published
- 2016
- Full Text
- View/download PDF
13. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary
- Author
-
Wolfgang A. Schmidt, Sarah L. Mackie, Marco A. Cimmino, Lorna Neill, Tanaz A. Kermani, Peter A. Merkel, Peter Lanyon, Alexandre Wagner Silva de Souza, Susan P Mollan, Dorothy Byrne, Asad Khan, Chetan Mukhtyar, Christina Duftner, Madeline Whitlock, Dario Camellino, Simone Appenzeller, Elaine Yacyshyn, Eric L. Matteson, Maria C. Cid, Alfred Mahr, Marwan Bukhari, Haner Direskeneli, Christian D Mallen, Eoin O' Sullivan, Justin C Mason, Richard A. Watts, Christian Dejaco, Maria Sandovici, Raashid Luqmani, Frank Buttgereit, Elisabeth Brouwer, Gary Reynolds, Bhaskar Dasgupta, Steven R. Ytterberg, Kate Gilbert, Solange Gonzalez-Chiappe, Mackie, Sarah L., Dejaco, Christian, Appenzeller, Simone, Camellino, Dario, Duftner, Christina, Gonzalez-Chiappe, Solange, Mahr, Alfred, Mukhtyar, Chetan, Reynolds, Gary, de Souza, Alexandre Wagner S., Brouwer, Elisabeth, Bukhari, Marwan, Buttgereit, Frank, Byrne, Dorothy, Cid, Maria C., Cimmino, Marco, Direskeneli, Haner, Gilbert, Kate, Kermani, Tanaz A., Khan, Asad, Lanyon, Peter, Luqmani, Raashid, Mallen, Christian, Mason, Justin C., Matteson, Eric L., Merkel, Peter A., Mollan, Susan, Neill, Lorna, O' Sullivan, Eoin, Sandovici, Maria, Schmidt, Wolfgang A., Watts, Richard, Whitlock, Madeline, Yacyshyn, Elaine, Ytterberg, Steven, Dasgupta, Bhaskar, Translational Immunology Groningen (TRIGR), and Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI)
- Subjects
medicine.medical_specialty ,diagnosis ,POLYMYALGIA-RHEUMATICA ,large-vessel vasculitis ,RECOMMENDATIONS ,Polymyalgia rheumatica ,chemistry.chemical_compound ,DOUBLE-BLIND ,Tocilizumab ,Rheumatology ,Internal medicine ,Large vessel vasculitis ,medicine ,MANAGEMENT ,Humans ,Pharmacology (medical) ,guidelines ,BSR ,Glucocorticoids ,TOCILIZUMAB ,Ultrasonography ,Executive summary ,treatment ,business.industry ,giant cell arteritis ,BHPR GUIDELINES ,Guideline ,medicine.disease ,Dermatology ,investigations ,Giant cell arteritis ,chemistry ,temporal arteritis ,TRIAL ,COLLEGE ,Vasculitis ,business - Published
- 2020
14. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis
- Author
-
Alfred Mahr, Eric L. Matteson, Maria Sandovici, Elisabeth Brouwer, Justin C Mason, Tanaz A. Kermani, Gary Reynolds, Madeline Whitlock, Lorna Neill, Alexandre Wagner Silva de Souza, Wolfgang A. Schmidt, Dario Camellino, Marco A. Cimmino, Chetan Mukhtyar, Susan P Mollan, Bhaskar Dasgupta, Christian D Mallen, Christian Dejaco, Steven R. Ytterberg, Raashid Luqmani, Elaine Yacyshyn, Frank Buttgereit, Richard A. Watts, Sarah L. Mackie, Eoin O' Sullivan, Marwan Bukhari, Dorothy Byrne, Haner Direskeneli, Kate Gilbert, Asad Khan, Peter A. Merkel, Peter Lanyon, Solange Gonzalez-Chiappe, Christina Duftner, Simone Appenzeller, Maria C. Cid, Mackie, Sarah L., Dejaco, Christian, Appenzeller, Simone, Camellino, Dario, Duftner, Christina, Gonzalez-Chiappe, Solange, Mahr, Alfred, Mukhtyar, Chetan, Reynolds, Gary, de Souza, Alexandre Wagner S., Brouwer, Elisabeth, Bukhari, Marwan, Buttgereit, Frank, Byrne, Dorothy, Cid, Maria C., Cimmino, Marco, Direskeneli, Haner, Gilbert, Kate, Kermani, Tanaz A., Khan, Asad, Lanyon, Peter, Luqmani, Raashid, Mallen, Christian, Mason, Justin C., Matteson, Eric L., Merkel, Peter A., Mollan, Susan, Neill, Lorna, O' Sullivan, Eoin, Sandovici, Maria, Schmidt, Wolfgang A., Watts, Richard, Whitlock, Madeline, Yacyshyn, Elaine, Ytterberg, Steven, Dasgupta, Bhaskar, Imperial College Healthcare NHS Trust- BRC Funding, Translational Immunology Groningen (TRIGR), and Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI)
- Subjects
medicine.medical_specialty ,COLOR DUPLEX ULTRASONOGRAPHY ,diagnosis ,POPULATION-BASED COHORT ,MEDLINE ,Placebo-controlled study ,POLYMYALGIA-RHEUMATICA ,TEMPORAL ARTERITIS ,large-vessel vasculitis ,PLACEBO-CONTROLLED TRIAL ,AORTIC-ANEURYSM ,1117 Public Health and Health Services ,Polymyalgia rheumatica ,Aortic aneurysm ,LARGE-VESSEL INVOLVEMENT ,DOUBLE-BLIND ,Rheumatology ,Internal medicine ,Large vessel vasculitis ,medicine ,Humans ,Pharmacology (medical) ,guidelines ,Science & Technology ,treatment ,business.industry ,giant cell arteritis ,1103 Clinical Sciences ,Guideline ,PERMANENT VISUAL-LOSS ,medicine.disease ,Arthritis & Rheumatology ,investigations ,Giant cell arteritis ,1107 Immunology ,RISK-FACTORS ,Radiology ,business ,Life Sciences & Biomedicine - Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.